Acadia Pharma (ACAD) Tops Q1 EPS by 5c, Misses on Revenue; Offers FY24 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. CHKP
5. ON
6. CRWD
7. HNGE
8. INSP
9. MRVL
10. MTCH

Go back to Acadia Pharma (ACAD) Tops Q1 EPS by 5c, Misses on Revenue; Offers FY24 Guidance

Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview

May 8, 2024 4:05 PM EDT

- First quarter NUPLAZID® (pimavanserin) net product sales of $129.9 million

- First quarter DAYBUE (trofinetide) net product sales of $75.9 million

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2024.

In the first quarter of 2024, Acadia delivered net product sales of $205.8 million, representing 74% revenue growth year over year, primarily due to the addition of our second commercial product, DAYBUE for the treatment of Rett syndrome, combined with growth in market share of NUPLAZID for the... More